{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:25:55Z","timestamp":1757611555185,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2016,3,12]]},"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate clinical response by baseline disease duration using 2-year data from the AMPLE trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomised to subcutaneous abatacept 125\u2005mg weekly or adalimumab 40\u2005mg bi-weekly, with background methotrexate. As part of a post hoc analysis, the achievement of validated definitions of remission (Clinical Disease Activity Index (CDAI) \u22642.8, Simplified Disease Activity Index (SDAI) \u22643.3, Routine Assessment of Patient Index Data 3 (RAPID3) \u22643.0, Boolean score \u22641), low disease activity (CDAI &lt;10, SDAI &lt;11, RAPID3 \u22646.0), Health Assessment Questionnaire-Disability Index response and American College of Rheumatology responses were evaluated by baseline disease duration (\u22646 vs &gt;6\u2005months). Disease Activity Score 28 (C-reactive protein) &lt;2.6 or \u22643.2 and radiographic non-progression in patients achieving remission were also evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 646 patients were randomised and treated (abatacept, n=318; adalimumab, n=328). In both treatment groups, comparable responses were achieved in patients with early rheumatoid arthritis (\u22646\u2005months) and in those with later disease (&gt;6\u2005months) across multiple clinical measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Abatacept or adalimumab with background methotrexate were associated with similar onset and sustainability of response over 2\u2005years. Patients treated early or later in the disease course achieved comparable clinical responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>NCT00929864, Post-results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2015-000210","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T22:50:10Z","timestamp":1461106210000},"page":"e000210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration"],"prefix":"10.1136","volume":"2","clinical-trial-number":[{"clinical-trial-number":"nct00929864","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael","family":"Schiff","sequence":"first","affiliation":[{"name":"University of Colorado, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E","family":"Weinblatt","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Valente","sequence":"additional","affiliation":[{"name":"Arthritis Center of Nebraska, Lincoln, Nebraska, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[{"name":"Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Massarotti","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Yazici","sequence":"additional","affiliation":[{"name":"New York University Hospital for Joint Diseases, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"2025090313090942000_2.1.e000210.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204920"},{"key":"2025090313090942000_2.1.e000210.2","unstructured":"US Food and Drug Administration (FDA). Guidance for industry. Rheumatoid arthritis: developing drug products for treatment. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM354468.pdf (accessed 23 Mar 2015)."},{"key":"2025090313090942000_2.1.e000210.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2025090313090942000_2.1.e000210.4","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313090942000_2.1.e000210.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091454"},{"key":"2025090313090942000_2.1.e000210.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.149765"},{"key":"2025090313090942000_2.1.e000210.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110262"},{"key":"2025090313090942000_2.1.e000210.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"2025090313090942000_2.1.e000210.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203843"},{"key":"2025090313090942000_2.1.e000210.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100208"},{"key":"2025090313090942000_2.1.e000210.11","first-page":"35","article-title":"Effect of biologic agents on radiographic progression of rheumatoid arthritis","volume":"3","author":"Tobon","year":"2010","journal-title":"Rep Med Imaging"},{"key":"2025090313090942000_2.1.e000210.12","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9"},{"key":"2025090313090942000_2.1.e000210.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh199"},{"key":"2025090313090942000_2.1.e000210.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.24661"},{"key":"2025090313090942000_2.1.e000210.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"2025090313090942000_2.1.e000210.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.30463"},{"key":"2025090313090942000_2.1.e000210.17","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"2025090313090942000_2.1.e000210.18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"van der Heijde","year":"1989","journal-title":"Lancet"},{"key":"2025090313090942000_2.1.e000210.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2025090313090942000_2.1.e000210.20","first-page":"1","article-title":"Early rheumatoid arthritis\u2014is there a window of opportunity?","volume":"80","author":"Cush","year":"2007","journal-title":"J Rheumatol Suppl"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2015-000210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:09:18Z","timestamp":1756930158000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2015-000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,19]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1136\/rmdopen-2015-000210"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2015-000210","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}